RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as personalized content. Please see our Privacy Policy for more information.

The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.

About the Regulatory Profession

The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.

Regulatory Code of Ethics

One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.

Regulatory Competency Framework

Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.

Regulatory Convergence

Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.

Senate Advances Compounding, Track and Trace Legislation with an Eye on July Passage

The US Senate's Health, Education, Labor and Pensions (HELP) Committee has advanced two long-sought-after proposals that would overhaul the framework by which the US Food and Drug Administration (FDA) regulates the compounding, tracking and tracing of pharmaceutical products.

Pharmaceutical Compounding

The former comes after dozens of deaths and hundreds of injuries resulting from deficient compounding practices at a Massachusetts-based compounding pharmacy, the New England Compounding Center (NECC). Problems at that facility resulted in hundreds being infected with a rare strain of fungal meningitis. Furious legislators hauled top FDA officials before several hearings, demanding of them answers for why the agency did not stop those products from reaching market despite being made aware of general problems at the facility nearly a decade before and again in the interim years. FDA's answer: Thanks to several conflicting court cases and Congress itself, the agency lacks the statutory authority to inspect compounding facilities with the same vigor as it does traditional pharmaceutical manufacturers.

On 22 May 2013, the Senate HELP Committee unanimously passed the Pharmacy Compounding Quality and Accountability Act&nbsp;, which it said will help solve the problems now facing regulators by giving FDA new regulatory authority while preserving some of the structures inherent to the existing system. The passage came just as the committee released a new report illustrating some of the more egregious problems within the compounding sector, including the huge number of products being recalled by compounding pharmacies.

"The&nbsp;Pharmaceutical Compounding Quality and Accountability Act&nbsp;will clarify oversight of pharmaceutical compounding, leaving traditional pharmacies under the supervision of states, while enabling FDA to regulate compounding manufacturers, companies that make compounded sterile drugs without prescriptions, and ship them across state lines," Sen. Tom Harkin (D-IA) wrote in a statement.

The legislation contains several provisions called for by FDA and legislators alike, including:

FDA will now have explicit authority to treat compounded products as a "new drug" under the Federal Food, Drug and Cosmetic Act (FD&amp;C Act)

Compounders would be banned from making copies of FDA-approved drugs

A new category of "compounding manufacturers" would be created, while leaving traditional compounders with fewer restrictions

Any compounder that creates sterile products would be subject to greater regulatory oversight

Compounding pharmacies would need to register with FDA

Compounders would need to pay user fees to FDA ($15,000 each per year) to support oversight measures such as inspections and registration

The New York Timesreports that congressional staffers say the bill will most likely be considered by the full Senate in July, after which time it would need to be either passed by the House of Representatives, or reconciled with a similar bill now being considered by the House Energy and Commerce Committee.

Track and Trace

The latter of the Senate's two proposals, the Drug Supply Chain Security Act, also known as the track and trace bill, comes after repeated instances of counterfeit products entering the US supply chain. At issue for regulators is the ability to establish a trusted pedigree for a drug, allowing them to track a drug as it moves throughout the supply chain and trace it back to its point of origin when something goes wrong. As a Wall Street Journal investigation in 2012 showed, the path of a counterfeit drug product can span several countries and continents, and it's not always clear where something comes from.

The Senate's bill looks to alter that by instituting a number of new requirements on current manufacturers and distributors. Among them:

Lot-level tracking requirements established for drug products, with unit-level tracking in the future.

Product identifiers will need to be affixed to a product within four years of the date of the law's enactment.

Manufacturers may only distribute their products to authorized trading partners.

Within one year, manufacturers will need to have systems in place to identify counterfeit products in their possession.

National requirements established that pre-empt state laws.

New licensing requirements are put in place for wholesalers.

A new public database to track licensed wholesalers will be created.

FDA will publish draft guidance on track and trace requirements.

Regulators would have the request data from entities; information would not be kept in a real-time database.

Transaction history is required to be kept by entities, including manufacturers, for six years after the date of the transaction.

The bill passed the HELP Committee on 22 May 2013, and now moves to the full Senate for a vote, after which time it will need to be reconciled with the House of Representatives' version of the bill before being sent to the president for likely approval.&nbsp;